Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?

Oncologist

Volumn 7, Issue 3, 2002, Pages 226-233

  Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Combination chemotherapy; Metastatic non small cell lung cancer; Phase III studies

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TOPOTECAN; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0036076240     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-3-226     Document Type: Review

References (20)

1. Cancer statistics, 2002
2. Non small cell lung cancer
3. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
4. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group Study
5. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer
6. A randomized phase III trial of paclitaxel + carboplatin (PC) versus vinorelbine + cisplatin (VC) in NSCLC: A Southwest Oncology Group (SWOG) study
7. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer
8. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
9. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small cell lung cancer (NSCLC). Preliminary analysis
10. A EORTC randomized phase III trial of three chemotherapy regimen advanced non-small cell lung cancer (NSCLC)
11. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer
12. A multicenter randomized phase III study of docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer
13. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (DDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC)
14. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
15. Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated metastatic non-small cell lung cancer (NSCLC)
16. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
17. Phase I/II trial of ISIS 3521 an antisense inhibitor of PKC-Alpha with carboplatin and paclitaxel in non-small cell lung cancer
18. A phase II trial of the EGFR tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with EGFR expressing NSCLC
19. Intermittent oral ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, shows evidence of good tolerability and activity: Final results from a phase I study
20. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines